UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, DC 20549



FORM 10-Q/A

(Amendment No.
2)



(Mark One)

|   |                                                                                               |                   |          
|-- | --------------------------------------------------------------------------------------------- | ----------------- | ---------
|x  | QUARTERLY
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
|   |                                                                                              
|   | For
    the quarterly period ended                                                            | June
    30, 2019
|   |                                                                                               |                  
|OR
|  
|o  | TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
|   |                                                                                              
|   | For
    the transition period from ____________________________ to __________________________
|   |                                                                                              
|   | Commission
    file number                                                                    |                   | 000-49671



|MODULAR
    MEDICAL, INC.                                 
|----------------------------------------------------------
|(Exact
    Name of Registrant as Specified in its Charter)



|Nevada                                                              |  | 87-0620495                              
|------------------------------------------------------------------- |  | ----------------------------------------
|(State
    or Other Jurisdiction of Incorporation or Organization)  |  | (I.R.S.
    Employer Identification No.)
|                                                                    |  |                                         
|800
    West Valley Parkway, Suite 203, Escondido, California 92025
|(Address
    of Principal Executive Offices) (Zip Code)            



|(949)
    370-9062                                                                    
|--------------------------------------------------------------------------------------
|(Registrant’s
    Telephone Number, Including Area Code)                              
|                                                                                      
|N/A                                                                                   
|(Former
    Name, Former Address and Former Fiscal Year, if Changed Since Last Report)



Indicate by
check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.



Yes x No o



Indicate by
check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files).



YesxNoo



Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

|                             |                               
|---------------------------- | ------------------------------
|Large
    accelerated filero | Accelerated
    filero        
|Non-accelerated
    filero   | Smaller
    reporting companyx
|                             | Emerging
    growth companyx  



If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o



Indicate by
check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).



YesoNox



Securities
registered pursuant to Section 12(b) of the Act:



|Title
    of each class | Trading
    Symbol(s) | Name
    of each exchange on which registered
|----------------------- | --------------------- | ---------------------------------------------
|                        |                       |                                              



The
number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 17,820,261 as of October
17, 2019.









EXPLANATORY
NOTE



Modular Medical, Inc. filed its Quarterly
Report on Form 10-Q for the quarter ended June 30, 2019 with the Securities and Exchange Commission on August 14, 2019 (the “Original
Filing”). The Original Filing was subsequently amended on Form 10-Q/A on August 21, 2019 (the “Amended Filing”).
We are filing this Amendment No. 2 (this “Amended Filing No. 2”) on Form 10-Q/A to amend the Amended Filing. The purpose
of this Amended Filing No. 2 is to revise Item 4 of Part I of the Amended Filing. This Amended Filing No. 2 does not otherwise
modify or update disclosures in the Amended Filing or change our previously reported financial statements and other financial
disclosures.



Unless
expressly indicated or the context requires otherwise, the terms “Modular Medical, Inc.,” “Modular Medical,”
“Company,” “we,” “us,” and “our” in this refer to Modular Medical, Inc. (f/k/a
Bear Lake Recreation, Inc.), a Nevada corporation, and may include Modular Medical, Inc.’s wholly-owned subsidiary, Quasuras,
Inc., a Delaware corporation.

2







PART I—FINANCIAL
INFORMATION



Item 4. Controls
and Procedures



Disclosure
Controls and Procedures.

Our management
is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree
of compliance with the policies or procedures may deteriorate.



Under the supervision
and with the participation of our management, including our Chief Executive Officer, we conducted an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934. Based upon that evaluation, our management concluded that our Company’s disclosure controls and procedures
were not effective as of the end of the period covered by this report, as noted below in management’s report on internal control
over financial reporting.



Changes in
Internal Control over Financial Reporting.

During the three
months ended June 30, 2019, there was no change in our internal control over financial reporting that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.”



Management’s
Report on Internal Control over Financial Reporting

Our management
assessed the effectiveness of our internal control over financial reporting as of March 31, 2019. In making this assessment, it
used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal
Control-Integrated Framework. Based on its evaluation, our management concluded that there were material weaknesses in our internal
control over financial reporting and concluded that our internal controls over financial reporting were not effective as of March
31, 2019. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting
such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not
be prevented or detected on a timely basis.



The material
weaknesses related to inadequate internal controls over financial reporting, and the lack of segregation of duties in our financial
reporting process. We do not have a separately designated audit committee or independent director. To remediate these material
weaknesses, we hired a full-time accounting manager to assist in remedying weaknesses by implementing new policies and procedures
to ensure effective internal control over financial reporting.





Part II - OTHER INFORMATION



Item 6. Exhibits



|Exhibit
    No. |  | Description
    of Document                                                                                                                                           
|--------------- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
|31.1            |  | Certification
    of Paul M. DiPerna pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002.
|                |  |                                                                                                                                                                       





3





SIGNATURES



Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.



MODULAR MEDICAL,
INC.

|      |                      |  |     |                                                                                       
|----- | -------------------- |  | --- | --------------------------------------------------------------------------------------
|Date: | October
    18, 2019 |  | By: | /s/Paul
    M. DiPerna                                                                
|      |                      |  |     | Paul
    M. DiPerna                                                                   
|      |                      |  |     | Chief
    Executive Officer, Chief Financial Officer,Secretary, Treasurer and Director
|      |                      |  |     | (principal executive,
    financial and accounting officer)                           

4